Gilead Sciences developed Yeytuo for HIV prevention, which received authorization from the European Commission following EMA assessment.
2 reports, 2 independent
Updated Aug 26
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences developed Yeytuo for HIV prevention, which received authorization from the European Commission following EMA assessment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Gilead Sciences
American company
-
European Commission
executive branch of the European Union
- The European Commission is boosting emergency aid and providing migration financing across the Middle East, Great Lakes, and Kenya.
- Nirmala Sitharaman, Valdis Dombrovskis, Kristalina Georgieva, and other high-level officials discussed deepening the India-EU Economic Partnership, the India-EU FTA, and cooperation through the Trade and Technology Council.
Coverage
Newest first; wire copies grouped- Pharmaceutical TechnologyGilead’s Yeytuo approved in EU, boosting its blockbuster potential The European Commission (EC) has approved Gilead’s Yeytuo (lenacapavir) for the prevention of HIV infection, consolidating the injec
- Business WireEuropean Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention – Yeytuo® is the First and Only European Commission (EC)-Authorized HIV PrEP Option Offering 6 Months of Protectio